breast-pathology-2017-scientifictracks-abstracts

5 / 26

Page 30
Notes:
conferenceseries.com
Volume 2, Issue 4 (Suppl) Breast Can Curr Res, an open access journal Breast Pathology 2017
August 23-24, 2017
August 23-24, 2017 Toronto, Canada
4th World Congress on
Breast Pathology and Cancer Diagnosis
Hallgeir Rui, Breast Can Curr Res 2017, 2:4 (Suppl)
DOI: 10.4172/2572-4118-C1-008
Use of quantitative immunohistochemistry to evaluate marker expression in breast cancer
Hallgeir Rui
Medical College of Wisconsin, USA
Breast cancer is a heterogenous disease and there is a great need for further individualized treatment. Due to extensive
intertumor and intratumor heterogeneity, immunohistochemistry provides valuable spatially resolved marker analysis
at the tissue level. Pathologists typically evaluate protein marker expression visually in formalin-fixed paraffin-embedded
tumor sections by chromogenic immunohistochemistry. However, pathologist scoring of chromogen staining intensity
is subjective and provides only reduced data that is discrete, either ordinal (e.g. 1, 2, 3) or nominal (negative/positive). In
contrast, emerging digital pathology platforms allow quantification of chromogen or fluorescence signals by computer-assisted
image analysis, providing continuous signal intensity values. Fluorescence-based immunohistochemistry (IF-IHC) provides
greater dynamic signal range than chromogen-immunohistochemistry. Combined with image analysis software, fluorescence-
based immunohistochemistry holds potential for enhanced sensitivity and greater analytic resolution resulting in more robust
quantification. However, commercial fluorescence scanners and image analysis software differ in features and capabilities.
Vendors’ claims of objective quantitative immunohistochemistry are difficult to validate since pathologist scoring is subjective
and, importantly, there is no accepted gold standard to measure against. We will present validation studies and progress
with quantitative immunohistochemistry on large cohorts of breast cancer using different technologies. The path towards
implementation of objective tumor marker quantification in pathology laboratories will be discussed.
Biography
Hallgeir Rui is a PhD holder and serves as the WBCS Endowed Professor of Breast Cancer Research in the Department of Pathology at the Medical College
of Wisconsin, Milwaukee, WI. He has previously held positions at Thomas Jefferson University, Philadelphia, PA, Georgetown University, Washington DC, and
Uniformed Services University, Bethesda, MD. He completed his Post-doctoral training at NCI, Frederick, MD and Moffitt Cancer Center, Tampa, FL. He received
his MD and PhD degrees at the University of Oslo, Norway. His laboratory research is centered on analyses of human breast cancer to improve tailored therapy.